Astrazeneca stock drops 8.14% last month, underperforming market

From Nasdaq: 2024-09-20 18:15:22

In the latest trading session, Astrazeneca (AZN) closed at $78.38, down 0.66%. The stock has dropped 8.14% in the last month, underperforming the Medical sector. Analysts expect an EPS of $1.07 and revenue of $13.14 billion in the upcoming release, with estimates for full-year earnings of $4.05 per share and revenue of $52.48 billion.

Investors should monitor analyst projections for Astrazeneca, as revisions can indicate short-term business trends. Changes are closely tied to stock price performance, with Zacks Rank providing actionable insight. With a Zacks Rank of #3 (Hold) and unchanged EPS estimate, it’s essential to track these metrics in upcoming trading sessions.

Astrazeneca’s valuation includes a Forward P/E ratio of 19.47, higher than the industry average of 15.96. The PEG ratio stands at 1.49, slightly lower than the industry average. The Large Cap Pharmaceuticals industry is ranked 82 out of 250+ industries, indicating positive strength. Monitor stock-impacting metrics closely for future insights.

Discover 5 stocks set to double, handpicked by Zacks experts for potential gains of +100% or more in 2024. Previous recommendations have seen significant returns. These picks are under the radar, providing a ground-floor opportunity. Get the latest recommendations from Zacks Investment Research to stay informed and potentially capitalize on these opportunities.



Read more at Nasdaq: Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights